ES2721001T3 - Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa - Google Patents

Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa Download PDF

Info

Publication number
ES2721001T3
ES2721001T3 ES15743281T ES15743281T ES2721001T3 ES 2721001 T3 ES2721001 T3 ES 2721001T3 ES 15743281 T ES15743281 T ES 15743281T ES 15743281 T ES15743281 T ES 15743281T ES 2721001 T3 ES2721001 T3 ES 2721001T3
Authority
ES
Spain
Prior art keywords
treat
compositions
methods
neurodegenerative disease
isoindoline derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15743281T
Other languages
English (en)
Inventor
Gilbert Rishton
Susan Catalano
Gary Look
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognition Therapeutics Inc
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Application granted granted Critical
Publication of ES2721001T3 publication Critical patent/ES2721001T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/62Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Compuesto de fórmula:**Fórmula** o una sal farmacéuticamente aceptable del mismo.
ES15743281T 2014-01-31 2015-01-30 Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa Active ES2721001T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461934528P 2014-01-31 2014-01-31
PCT/US2015/013754 WO2015116923A1 (en) 2014-01-31 2015-01-30 Isoindoline compositions and methods for treating neurodegenerative disease

Publications (1)

Publication Number Publication Date
ES2721001T3 true ES2721001T3 (es) 2019-07-26

Family

ID=53757753

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15743281T Active ES2721001T3 (es) 2014-01-31 2015-01-30 Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
ES19154222T Active ES2915833T3 (es) 2014-01-31 2015-01-30 Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19154222T Active ES2915833T3 (es) 2014-01-31 2015-01-30 Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular

Country Status (16)

Country Link
US (5) US9796672B2 (es)
EP (3) EP3498692B1 (es)
JP (1) JP6517827B2 (es)
KR (1) KR102331422B1 (es)
CN (1) CN106163516B (es)
AU (1) AU2015210852B2 (es)
BR (1) BR112016017808B1 (es)
CA (1) CA2938212C (es)
DK (2) DK3099296T3 (es)
ES (2) ES2721001T3 (es)
HK (1) HK1225651A1 (es)
IL (1) IL247003B (es)
MX (1) MX368755B (es)
NZ (1) NZ722599A (es)
RU (1) RU2692258C2 (es)
WO (1) WO2015116923A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
UA123256C2 (uk) 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
JP6348978B2 (ja) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー グリオキサミド置換ピロールアミド誘導体およびb型肝炎を処置するための医薬品としてのその使用
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
BR112016017808B1 (pt) 2014-01-31 2022-07-12 Cognition Therapeutics, Inc Composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
EP3448520A4 (en) * 2016-04-29 2020-07-29 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
CN107162944B (zh) * 2017-04-27 2019-02-26 湖南化工研究院有限公司 2,3-二甲基苯甲硫醚的制备方法
KR102614814B1 (ko) * 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
EP3704092A4 (en) * 2017-11-01 2021-08-25 Cognition Therapeutics, Inc. ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
CA3116348A1 (en) * 2018-10-31 2020-05-07 Polycore Therapeutics Llc Method for synthesizing d3 dopamine receptor agonists
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
CN109734638A (zh) * 2019-03-08 2019-05-10 新昌县大船畈生物科技有限公司 一种食用香精香料的制备方法
CN109734639B (zh) * 2019-03-08 2020-10-09 漯河市卫龙生物技术有限公司 一种食用香精香料的制备方法
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
CN112694427B (zh) * 2019-10-23 2022-11-18 江西天宇化工有限公司 一种制备2,3-二甲基苯甲硫醚的方法
KR20220142477A (ko) * 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법
JP2023526515A (ja) 2020-05-20 2023-06-21 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ リソソーム蓄積症をヒスタチンペプチドで処置するための方法
KR20230118158A (ko) * 2020-12-11 2023-08-10 카그니션 테라퓨틱스, 인코퍼레이티드 건성 노년기 황반 변성 (amd)을 치료하기 위한 조성물
WO2024020059A1 (en) * 2022-07-18 2024-01-25 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
WO2024130030A1 (en) * 2022-12-14 2024-06-20 Fred Hutchinson Cancer Center Method for treating neurological diseases through glial pruning regulation

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
DE2753278A1 (de) 1977-11-30 1979-05-31 Basf Ag Aralkylpiperidinone
US4321386A (en) 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
DE3222152A1 (de) 1982-06-12 1983-12-15 Bayer Ag, 5090 Leverkusen Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
GR79758B (es) 1983-01-31 1984-10-31 Lilly Co Eli
JPS62283922A (ja) 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
US4958029A (en) * 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
JPH01180822A (ja) 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
JPH01305085A (ja) 1988-05-31 1989-12-08 Yamanouchi Pharmaceut Co Ltd ピリジルチアゾリジンカルボン酸アミド誘導体
JPH02215789A (ja) 1989-02-15 1990-08-28 Yamanouchi Pharmaceut Co Ltd チアゾロ[3,4―a]ピラジン誘導体
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
JPH045266A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69433714T2 (de) 1991-08-23 2005-03-31 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium - receptor aktive arylalkylamine
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
JPH06321781A (ja) 1993-05-13 1994-11-22 Yamanouchi Pharmaceut Co Ltd 血小板活性化因子拮抗剤
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
JP3522930B2 (ja) 1995-12-06 2004-04-26 花王株式会社 抗菌剤及びこれを含有する口腔用組成物
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp DIARYLSULTAME DERIVATIVES
CA2251625A1 (en) * 1996-04-24 1997-10-30 Yumiko Shibouta Fused imidazopyridine derivatives as antihyperlipidemic agents
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
CO4980891A1 (es) 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
EP1481061B1 (en) 2001-03-05 2011-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
AU2002332659A1 (en) 2001-08-21 2003-03-03 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
EE05374B1 (et) 2001-12-14 2011-02-15 Council�of�Scientific�and�Industrial�Research KompositsioonÁneurotserebrovaskulaarseteÁh„ireteÁravimiseksÁningÁmeetodÁsellesÁsisalduvaÁkurkumi?liÁvalmistamiseks
JP2004002517A (ja) 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
US20050020483A1 (en) 2003-06-12 2005-01-27 Donna Oksenberg Sigma ligands for neuronal regeneration and functional recovery
US7829562B2 (en) 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
BRPI0418634A (pt) 2004-03-12 2007-05-29 Egis Gyogyszergyar Nyrt composição farmacêutica combinada para a inibição do declìnio das funções cognitivas
CA2566202A1 (en) 2004-05-31 2005-12-08 Kaneka Corporation Agent for preventing/ameliorating life style-related diseases containing turmeric essential oil component
EP1794313B1 (en) 2004-06-21 2013-05-15 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005281783A1 (en) 2004-09-10 2006-03-16 Ucb Pharma, S.A. Sigma receptor ligands
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
US20060153772A1 (en) 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
AU2006222193B2 (en) 2005-03-05 2011-11-17 AbbVie Deutschland GmbH & Co. KG Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
CA2611489A1 (en) 2005-06-15 2006-12-28 Darrick S.H.L. Kim Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
MX2008011754A (es) 2006-03-17 2008-09-30 Herbalscience Singapore Pte Ltd Extractos y metodos que comprenden especies de curcuma.
WO2007112288A2 (en) 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2007126473A2 (en) 2006-04-10 2007-11-08 Oligomerix, Inc. Oligomerization of amyloid proteins
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
EP2066692B1 (en) 2006-09-08 2012-01-11 VIB, vzw Means and methods for the production of amyloid oligomers
US7723377B2 (en) 2006-09-29 2010-05-25 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20080131233A1 (en) 2006-10-17 2008-06-05 Yao Chun I Plate-shaped fastener device
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
US20080171757A1 (en) 2007-01-11 2008-07-17 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Serivces Methods to identify inhibitors of cell sickling
CA2719878C (en) 2007-04-26 2017-08-29 Yale University Prion protein as a receptor for amyloid-beta oligomers
MX2009012316A (es) 2007-05-15 2009-12-03 Helicon Therapeutics Inc Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12.
CN101121670A (zh) 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
US20090246191A1 (en) 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
US20110092554A1 (en) 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
CA2730804A1 (en) 2008-07-25 2010-01-28 Abbott Laboratories Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses
KR101515822B1 (ko) 2008-11-29 2015-04-29 더 타일랜드 리서치 펀드 바이러스와 타겟 세포의 상호작용 저해
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
DK2408905T3 (en) 2009-03-16 2017-08-28 Pangu Biopharma Ltd Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities
US7972164B2 (en) 2009-03-24 2011-07-05 Tyco Electronics Corporation Connector assembly with a latch
AU2010234518A1 (en) 2009-04-09 2012-02-02 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
ES2581178T3 (es) 2009-07-29 2016-09-01 Pharnext Nuevas herramientas de diagnóstico para enfermedad de Alzheimer
JP2013501006A (ja) * 2009-07-31 2013-01-10 コグニション セラピューティクス インク. 認知機能低下の阻害剤
US20150160228A1 (en) 2010-02-05 2015-06-11 Susan Catalano Compositions and method for determining the efficacy of amyloidosis treatments
WO2011106785A2 (en) 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2012027548A1 (en) 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
US20170049723A1 (en) 2011-02-02 2017-02-23 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
WO2013029060A2 (en) 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
BR112014004414A2 (pt) 2011-08-25 2017-03-28 Cognition Therapeutics Inc composições e métodos para tratar doença neurodegenerativa
AT511906B1 (de) 2011-08-30 2016-05-15 Blum Gmbh Julius Schublade
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
BR112016017808B1 (pt) 2014-01-31 2022-07-12 Cognition Therapeutics, Inc Composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
EP3704092A4 (en) * 2017-11-01 2021-08-25 Cognition Therapeutics, Inc. ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE
CN110283082A (zh) 2019-07-15 2019-09-27 泰州职业技术学院 一种3-苯基丙胺的制备方法
KR20220142477A (ko) 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법
KR20230118158A (ko) 2020-12-11 2023-08-10 카그니션 테라퓨틱스, 인코퍼레이티드 건성 노년기 황반 변성 (amd)을 치료하기 위한 조성물

Also Published As

Publication number Publication date
MX368755B (es) 2019-10-15
BR112016017808A8 (pt) 2020-06-30
US11691947B2 (en) 2023-07-04
CA2938212A1 (en) 2015-08-06
US20210009517A1 (en) 2021-01-14
US20240150288A1 (en) 2024-05-09
EP3099296A1 (en) 2016-12-07
EP4023294A1 (en) 2022-07-06
DK3498692T3 (da) 2022-05-16
US10611728B2 (en) 2020-04-07
RU2016134677A3 (es) 2018-09-14
BR112016017808A2 (pt) 2017-08-08
DK3099296T3 (en) 2019-04-15
EP3099296B1 (en) 2019-01-30
US10207991B2 (en) 2019-02-19
EP3498692B1 (en) 2022-03-16
HK1225651A1 (zh) 2017-09-15
JP6517827B2 (ja) 2019-05-22
NZ722599A (en) 2022-05-27
MX2016009845A (es) 2017-02-22
IL247003B (en) 2019-09-26
KR102331422B1 (ko) 2021-11-25
US20180086703A1 (en) 2018-03-29
ES2915833T3 (es) 2022-06-27
US20170144970A1 (en) 2017-05-25
EP3099296A4 (en) 2017-07-19
KR20160108564A (ko) 2016-09-19
US9796672B2 (en) 2017-10-24
WO2015116923A1 (en) 2015-08-06
BR112016017808B1 (pt) 2022-07-12
EP3498692A1 (en) 2019-06-19
CN106163516B (zh) 2019-05-28
IL247003A0 (en) 2016-09-29
AU2015210852A1 (en) 2016-08-11
RU2692258C2 (ru) 2019-06-24
US20190210966A1 (en) 2019-07-11
CN106163516A (zh) 2016-11-23
RU2016134677A (ru) 2018-03-01
AU2015210852B2 (en) 2019-01-24
CA2938212C (en) 2023-03-14
JP2017507122A (ja) 2017-03-16

Similar Documents

Publication Publication Date Title
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
SA519410025B1 (ar) مثبطات ديميثيلاز-1 نوعي لللايسين
EA201691582A1 (ru) Новые фармацевтические препараты
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201691940A1 (ru) Новые соединения
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
PE20151654A1 (es) Inhibidores de cdc7
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2016002940A1 (es) Derivado de carotenoides, sal farmacéuticamente aceptable del mismo, o éster o amida farmacéuticamente aceptables del mismo
EP3169784A4 (en) Organic compositions to treat apoc3-related diseases
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
SV2017005381A (es) Compuestos de imidazopiridazina
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
EA201791945A1 (ru) Пирролидинкарбоксамидопроизводные и способы их получения и их применение
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201792264A1 (ru) Способы лечения воспалительных заболеваний